Brevan Howard Capital Management’s Quest Diagnostics DGX Stock Holding History

Brevan Howard Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.29M	Buy	15,507 +13,701	+759%	+$2.69M	0.02%	510
2026 Q1	$354K	Sell	1,806 -10,118	-85%	-$1.97M	﹤0.01%	1518
2025 Q4	$2.07M	Buy	11,924 +10,293	+631%	+$1.87M	0.02%	480
2025 Q3	$311K	Buy	1,631 +471	+41%	+$83.6K	﹤0.01%	1549
2025 Q2	$208K	Buy	+1,160	New	+$201K	﹤0.01%	1697
2024 Q4	–	Sell	-4,647	Closed	-$721K	–	1128
2024 Q3	$721K	Sell	4,647 -1,124	-19%	-$168K	0.01%	569
2024 Q2	$790K	Buy	5,771 +2,056	+55%	+$282K	0.01%	449
2024 Q1	$495K	Buy	+3,715	New	+$482K	﹤0.01%	470

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Brevan Howard Capital Management's DGX Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Quest Diagnostics (DGX) stake by 759% in Q2 2026, buying an estimated $2.69M and bringing the position to 15,507 shares worth $3.29M. The position accounts for 0.02% of the portfolio, ranked #510.

Brevan Howard Capital Management first reported a position in DGX in Q1 2024 and has held it in 8 quarters since. 1,111 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Brevan Howard Capital Management held 15,507 shares of Quest Diagnostics worth $3.29M as of Q2 2026.
Brevan Howard Capital Management bought 13,701 Quest Diagnostics shares in Q2 2026, an estimated $2.69M.
Quest Diagnostics made up 0.02% of Brevan Howard Capital Management's portfolio in Q2 2026, its #510 holding.
Brevan Howard Capital Management first reported a position in Quest Diagnostics in Q1 2024 and has held it in 8 quarters since.
1,111 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.